EV/EBITDA for West Pharmaceutical Services (WST)

West Pharmaceutical Services (WST) EV/EBITDA ratio is 28.2× as of June 5, 2026. The 5-year average is 29.5×. The sector median currently stands at 15.0×. The current ratio is at the 43th percentile of its own 10-year history.

West Pharmaceutical Services (WST) historical EV/EBITDA ratio has ranged from a low of 6.6× (2002) to a high of 50.0× (2021) in the available daily series.

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.